| Autor: |
Wong, George K.C., Chan, David Y.C., Siu, Deyond Y.W., Zee, Benny C.Y., Poon, Wai S., Chan, Matthew T.V., Gin, Tony, Leung, Michael, Zhu, X.L., Liang, M., Tan, H.B., Lee, M.W., Wong, C.K., Chan, T.K., Po, Y.C., Woo, P.Y., Chan, K.Y. |
| Zdroj: |
Stroke (Ovid); February 2015, Vol. 46 Issue: 2 p382-388, 7p |
| Abstrakt: |
Experimental evidence has indicated the benefits of simvastatin for the treatment of subarachnoid hemorrhage. Two randomized placebo-controlled pilot trials that used the highest clinically approved dose of simvastatin (80 mg daily) gave positive results despite the fact that a lower dose of simvastatin (40 mg daily) did not improve clinical outcomes. We hypothesized that a high dose of 80 mg of simvastatin daily for 3 weeks would reduce the incidence of delayed ischemic deficits after subarachnoid hemorrhage compared with a lower dose (40 mg of simvastatin daily) and lead to improved clinical outcomes. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
